During this month two patents by AstraZeneca were published on metabrotopic glutamate receptor potentiators. Here are the scaffolds of the compounds claimed.
United States Patent 7790717 makes explicit their interest in usingthe compounds for the treatment of Schizophrenia, but of course the languge covers all bases regarding neurological disorders. Modulators of metabotropic glutamate receptors as potentiators of the mGluR2 receptor, and are contemplated to be useful in therapy, in particular for the treatment of neurological and psychiatric disorders associated with glutamate dysfunction in an animal.
United States Patent 7790760 proposes the same medical uses for the potentiators it covers.
No comments:
Post a Comment